With covalent meds abuzz, RA Capital and Novartis lead $56M seed round for new startup
Seeing the successes of other covalent medicines companies, a group of blue-chip investors is lining up to take the next shot on goal.
RA Capital, typically known for its late-stage and crossover investments, is getting in on the ground floor at Hyku Biosciences, a new biotech that emerged from stealth Tuesday morning. RA and its incubator, RAVen, led a $56 million seed round for Hyku alongside Droia Ventures and Novartis Venture Fund.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
